PMID: 7542819Aug 1, 1995Paper

Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men

Urology
R S Kirby

Abstract

To assess the effects of doxazosin, a selective alpha 1 adrenoceptor inhibitor, on blood pressure and urinary flow in normotensive and hypertensive (sitting diastolic blood pressure more than 90 mm Hg) men with prostatic hyperplasia (BPH). Patients (n = 232) with bladder outflow obstruction due to BPH, classified as normotensive or hypertensive, were enrolled into two, double-blind, placebo-controlled studies. After a washout period of at least 1 week, patients were randomized to doxazosin or placebo, and treatment was continued for 9 to 12 weeks. In addition to measures of standing and sitting blood pressures, the patients' response to treatment was also assessed with regard to urinary flow. Although the protocols differed, they were consistent enough to permit pooling of a number of variables. Results from the two studies demonstrated that doxazosin produced a clinically significant reduction in blood pressure only in hypertensive patients (systolic blood pressure/diastolic blood pressure: baseline 162/99 mm Hg, endpoint 143/89 mm Hg); little or no reduction was evident in normotensive patients (systolic blood pressure/diastolic blood pressure: baseline 139/82 mm Hg, endpoint 134/78 mm Hg). Similar effects in terms of uroflow...Continue Reading

References

Aug 1, 1987·British Journal of Urology·R S KirbyE J Milroy
Sep 23, 1989·BMJ : British Medical Journal·D E NealR J Webb
Oct 21, 1989·BMJ : British Medical Journal·P Abrams
Jan 1, 1986·British Journal of Clinical Pharmacology·V A Alabaster, M J Davey
Mar 1, 1993·British Journal of Urology·M F DrummondC K McPherson
Jan 1, 1993·Scandinavian Journal of Urology and Nephrology·M M ChristensenS E Husted

❮ Previous
Next ❯

Citations

Nov 12, 2009·Naunyn-Schmiedeberg's Archives of Pharmacology·Natasha KyprianouMartin C Michel
Feb 23, 1999·The Urologic Clinics of North America·H L Holtgrewe
Jul 7, 2007·Nature Clinical Practice. Urology·Karl-Erik Andersson, Christian Gratzke
Feb 16, 2005·Prostate Cancer and Prostatic Diseases·W D Steers, R S Kirby
Nov 3, 2005·Prostate Cancer and Prostatic Diseases·C HernandezM Moralejo
Jun 27, 2006·Prostate Cancer and Prostatic Diseases·R Kirby
Jun 26, 2001·British Journal of Clinical Pharmacology·M C MichelH Rübben
Aug 13, 1999·International Journal of Urology : Official Journal of the Japanese Urological Association·A FawzyF Gonzalez
Aug 11, 2001·The Journal of Clinical Hypertension·N MartellUNKNOWN HT-BPH Group
Jul 14, 2007·International Journal of Clinical Practice·M T RosenbergD A Ohl
Mar 25, 2008·Therapeutics and Clinical Risk Management·Angelo J Cambio, Christopher P Evans
Apr 20, 2014·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Nadir I OsmanChristopher R Chapple
Jan 28, 1998·Clinical Therapeutics·R Guthrie
Nov 15, 2011·Current Opinion in Urology·Herbert LeporBob Djavan
Mar 24, 2007·Clinical Therapeutics·Michael J Naslund, Martin Miner
May 15, 2004·BJU International·M J SpeakmanUNKNOWN British Association of Urological Surgeons
Jun 18, 2010·BJU International·Michael G Wyllie, Wayne J G Hellstrom
Jun 15, 2007·Expert Opinion on Pharmacotherapy·Jeetesh BhardwaRoger Kirby
Aug 28, 2004·Expert Opinion on Pharmacotherapy·Sheila A Doggrell
Sep 6, 2002·Hospital Medicine·Charlotte L FoleyRoger S Kirby
Feb 3, 2000·Hospital Medicine·T Lane, J Shah
Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Mar 12, 1999·British Journal of Clinical Pharmacology·R F SchäfersM C Michel
Jan 15, 2000·Scandinavian Journal of Urology and Nephrology. Supplementum·H Hedlund, P Hedlund
Feb 15, 1997·The Prostate·K E AnderssonM G Wyllie
Nov 28, 2009·The Urologic Clinics of North America·Gregory B AuffenbergKevin T McVary

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.